NA
PTCT icon

NewEdge Advisors’s PTC Therapeutics PTCT Stock Holding History

NewEdge Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-161
Closed -$4.92K – 3915
2024
Q2 		$4.92K Buy
+161
New +$5.22K ﹤0.01% 3101
2023
Q1 		– Sell
-21
Closed -$1 – 3968
2022
Q4 		$1 Buy
+21
New +$873 ﹤0.01% 4032

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's PTCT Position: Q3 2024 in Review

NewEdge Advisors sold out of PTC Therapeutics (PTCT) in Q3 2024, closing a stake of 161 shares — an estimated $4.92K sold.

NewEdge Advisors first reported a position in PTCT in Q4 2022 and held it in 2 quarters. The position peaked at $4.92K in Q2 2024. 202 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

  • NewEdge Advisors reported no remaining PTC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • NewEdge Advisors sold 161 PTC Therapeutics shares in Q3 2024, an estimated $4.92K.
  • NewEdge Advisors first reported a position in PTC Therapeutics in Q4 2022 and held it in 2 quarters.
  • NewEdge Advisors's PTC Therapeutics position peaked at $4.92K in Q2 2024.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.